Hypogonadism, or low testosterone, affected more than one in 10 HIV-positive men in a preliminary single-center study in France. That rate is two times higher than in the general population of similarly aged men.
In rural areas, scarce clinical resources exist for many people living with chronic infectious diseases -- or for the clinicians who provide care for them. But a program called Project ECHO is trying to turn that tide.
What are the hottest developments in HIV clinical science over the past year? Physician-researcher Adaora Adimora, M.D., M.P.H., brought us a brief tour of key highlights at the start of the IDWeek 2015 medical conference in San Diego.
A new single-tablet HIV regimen containing tenofovir alafenamide (TAF) offered better bone and kidney safety, according to a study presented at ICAAC/ICC 2015.
Douglas Dieterich, M.D., who specializes in liver disease at Mount Sinai Hospital, discusses the new generation of medications against hepatitis C (HCV).
This year at CROI, there were over 30 abstracts on cardiovascular disease and HIV, which is a noticeable increase from prior years. Here's a recap of some of those studies.
Handling metabolic issues in HIV-positive patients requires a "multifactorial solution particularly emphasizing lifestyle modification."
With the deaths of 500 health care workers in West Africa due to Ebola, the epidemic has brought on a public health emergency in a region that already has a shortage of care providers and resources.
The use of varenicline (Chantix) appears to be relatively safe in people living with HIV, and when combined with counseling, could significantly increase the number who are able to quit smoking, according to a CROI 2015 study.
The new formulation of tenofovir, tenofovir alafenamide (TAF), was associated with less harm to bones and kidneys than the older formulation, tenofovir disoproxil fumarate (TDF, Viread).